



Date: 03rd November, 2020

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. NOVEMBER 03, 2020

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. November 03, 2020 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2020.

Please find enclosed standalone and consolidated unaudited financial results for the quarter and half year ended on 30th September, 2020.

The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 01:20 P.M.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
STANDALONE FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF

ERIS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the quarter and half year ended 30 September 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama
(Partner)
(Membership No. 107723)
(UDIN:20107723AAAAALM8750)


Place: Mumbai
Date: November 3, 2020



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Eris Lifesciences Limited

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
	September 30, 2020 (Unaudited)	June 30, 2020 (Unaudited)	September 30, 2019 (Unaudited)	September 30, 2020 (Unaudited)	September 30, 2019 (Unaudited)	March 31, 2020 (Audited)
[₹ in Million except per share data]						
Revenue from Operations						
Sale of products	2,983.77	2,561.08	2,684.20	5,544.85	5,281.98	10,037.60
Other operating income	49.96	53.73	44.79	103.69	70.27	164.71
Total Revenue from Operations	3,033.73	2,614.81	2,728.99	5,648.54	5,352.25	10,202.31
Other Income	24.10	14.10	49.03	38.20	76.19	147.28
Total Income	3,057.83	2,628.91	2,778.02	5,686.74	5,428.44	10,349.59
Expenses						
Cost of materials consumed	293.84	258.09	181.98	551.93	337.36	768.81
Purchase of stock-in-trade	253.71	290.41	228.02	544.12	444.47	700.02
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10.24)	(107.20)	41.53	(117.44)	122.30	174.72
Employee benefits expense	543.38	523.93	467.54	1,067.31	915.30	1,917.32
Finance Costs	1.96	2.18	3.99	4.14	12.51	18.54
Depreciation and amortisation expense	92.11	90.54	103.82	182.65	205.68	448.82
Other expenses	753.71	649.40	737.86	1,403.11	1,457.11	3,085.44
Total Expenses	1,928.47	1,707.35	1,764.74	3,635.82	3,494.73	7,113.67
Profit before Tax	1,129.36	921.56	1,013.28	2,050.92	1,933.71	3,235.92
Tax Expense						
Current Tax	198.27	163.78	142.13	362.05	343.04	574.92
Deferred Tax	(123.83)	(113.53)	(44.18)	(237.36)	(144.24)	(251.74)
Total Tax Expense	74.44	50.25	97.95	124.69	198.80	323.18
Net Profit for the period / year	1,054.92	871.31	915.33	1,926.23	1,734.91	2,912.74
Other Comprehensive Income	(11.96)	(1.30)	(0.67)	(13.26)	(4.40)	(11.71)
Items that will not be reclassified to profit or loss	(18.39)	(2.00)	(1.03)	(20.39)	(6.77)	(18.00)
Income tax relating to items that will not be reclassified to profit or loss	6.43	0.70	0.36	7.13	2.37	6.29
Total Comprehensive Income	1,042.96	870.01	914.66	1,912.97	1,730.51	2,901.03
Paid Up Equity Share Capital (Face Value of ₹ 1 each)	135.78	135.78	137.52	135.78	137.52	135.78
Other Equity						12,861.23
Earnings Per Share (of ₹ 1 each) (not annualised) :						
Basic	7.77	6.42	6.66	14.19	12.62	21.23
Diluted	7.76	6.41	6.65	14.17	12.60	21.21

See accompanying notes to the standalone financial results



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial results

1. Statement of Standalone Assets and Liabilities

(₹ in Million)

Particulars	As at	As at
	September 30, 2020 (Unaudited)	March 31, 2020 (Audited)
I. ASSETS :		
(1) Non-current assets		
(a) Property, Plant and Equipment	708.71	789.01
(b) Right-of-use asset	36.79	51.24
(c) Goodwill	166.60	166.60
(d) Other Intangible assets	4,961.18	4,999.55
(e) Intangible assets under development	25.85	43.73
(f) Financial assets		
Investments	2,455.57	2,460.28
Other financial assets	93.10	82.37
(g) Income tax assets (net)	34.28	34.47
(h) Deferred tax assets (net)	1,886.13	1,641.65
(i) Other non-current assets	107.56	66.41
Total Non current assets	10,475.77	10,335.31
(2) Current assets		
(a) Inventories	755.76	654.60
(b) Financial assets		
Investments	1,355.79	742.74
Trade receivables	1,627.44	1,408.22
Cash and cash equivalents	466.82	649.31
Other bank balances	0.20	0.19
Loans	207.28	18.70
Other financial assets	167.54	99.50
(c) Other current assets	995.93	922.71
Total Current assets	5,576.76	4,495.97
TOTAL- ASSETS	16,052.53	14,831.28
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Equity Share capital	135.78	135.78
(b) Other Equity	14,036.43	12,861.23
Total Equity	14,172.21	12,997.01
(2) Non-current Liabilities		
(a) Financial Liabilities		
Lease Liabilities	38.22	48.54
Other financial liabilities	1.73	18.93
(b) Long-term provisions	291.22	241.32
(c) Other non-current liabilities	26.41	31.07
Total Non-current liabilities	357.58	339.86
(3) Current liabilities		
(a) Financial Liabilities		
Trade payables		
i) Due to Micro and Small Enterprises	87.59	32.39
ii) Due to other than Micro and Small Enterprises	758.49	866.88
Lease Liabilities	33.01	56.94
Other financial liabilities	52.72	14.90
(b) Short-term provisions	302.72	297.58
(c) Other current liabilities	189.17	172.30
(d) Income tax liabilities (net)	99.04	53.42
Total Current liabilities	1,522.74	1,494.41
Total Liabilities	1,880.32	1,834.27
TOTAL- EQUITY AND LIABILITIES	16,052.53	14,831.28



2. Statement of Standalone Condensed Cash Flows for the Half Year ended September 30, 2020		
		(₹ in Million)
Particulars	For Half Year Ended September 30, 2020 (Unaudited)	For Half Year Ended 30th September, 2019 (Unaudited)
Net cash flow from operating activities		
Profit before tax	2,050.92	1,933.71
Operating profit before working capital changes	2,213.68	2,122.03
A) Net cash flow from operating activities	1,501.11	1,345.59
B) Net cash flow from / (used in) investing activities	(893.77)	497.41
C) Net cash (used) in financing activities	(789.83)	(1,807.51)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(182.49)	35.49
Add : Cash and cash equivalents at the beginning of the period	649.31	64.64
Cash and cash equivalents at end of the period	466.82	100.13

3. The above statement of unaudited financial results ("the Statement") of the Company have been recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 03, 2020. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
4. The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
5. The Company continues to observe the Covid-19 impact on its business. This covers the monitoring of its impact on its supply-chain and customers. Conclusions on significant accounting judgements and estimates have been drawn after exercising requisite due care. Such judgements and estimates include, inter-alia, recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available as of the date of preparing the Company's financial results for the quarter and half year ended September 30, 2020.
6. Other Income includes Net Gain/(Loss) on fair value of financial assets, net gain on sale of investments, interest income, deferred capital subsidy and sundry creditors written back.
7. The Parliament of India has approved the Code of Social security, 2020 ("the Code") which, inter alia, deals with employee benefits during employment and post employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified and the rules for quantifying the financial impact are also yet to be issued. In view of this, the impact of the change, if any, will be assessed and recognised post notification of the relevant provisions.
8. Figures for the previous periods / year have been regrouped wherever considered necessary.

For Eris Lifesciences Limited,



Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: November 03, 2020

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
CONSOLIDATED FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF

ERIS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and half year ended 30 September 2020 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - i. Eris Lifesciences Limited (Parent)
 - ii. Aprica Healthcare Limited (Subsidiary) – (Formerly known as Aprica Healthcare Private Limited)
 - iii. Kinedex Healthcare Private Limited (Subsidiary)
 - iv. Eris Therapeutics Private Limited (Subsidiary)
 - v. UTH Healthcare Limited (Subsidiary)
 - vi. Eris Healthcare Private Limited (Subsidiary)
 - vii. Eris Pharmaceuticals Private Limited (Subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information / financial results of all 6 subsidiaries included in the consolidated unaudited financial results, whose interim financial information / financial results, before giving effect to the Consolidation adjustments, reflect total assets of Rs. 1309.77 Millions as at September 30, 2020 and total revenues of Rs. 356.48 Millions and Rs. 769.10 Millions for the quarter and half year ended September 30, 2020 respectively, total net profit after tax of Rs. 23.83 Millions and Rs. 47.52 Millions for the quarter and half year ended September 30, 2020 respectively and total comprehensive income of Rs. 23.71 Millions and Rs. 47.28 Millions for the quarter and half year ended September 30, 2020 respectively and net cash flows of Rs. 21.56 Millions for the half year ended September 30, 2020, as considered in the Statement. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama
Partner
(Membership No. 107723)
(UDIN: 20107723AAAAALN1063)

Place: Mumbai
Date: November 3, 2020



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
	September 30, 2020 (Unaudited)	June 30, 2020 (Unaudited)	September 30, 2019 (Unaudited)	September 30, 2020 (Unaudited)	September 30, 2019 (Unaudited)	March 31, 2020 (Audited)
[₹ in Million except per share data]						
Revenue from Operations						
Sale of products	3,252.67	2,880.82	2,804.56	6,133.49	5,523.45	10,581.83
Other operating income	47.25	51.60	43.38	98.85	67.49	158.76
Total Revenue from Operations	3,299.92	2,932.42	2,847.94	6,232.34	5,590.94	10,740.59
Other Income	20.84	13.39	51.70	34.23	79.96	153.96
Total Income	3,320.76	2,945.81	2,899.64	6,266.57	5,670.90	10,894.55
Expenses						
Cost of materials consumed	293.84	258.09	181.98	551.93	337.36	768.81
Purchase of stock-in-trade	366.28	520.11	232.70	886.39	411.06	732.43
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(21.83)	(202.36)	42.53	(224.19)	167.72	214.07
Employee benefits expense	599.99	570.97	505.11	1,170.96	976.60	2,056.93
Finance Costs	4.52	4.05	5.14	8.57	14.19	21.62
Depreciation and amortisation expense	105.61	103.62	117.31	209.23	232.42	502.58
Other expenses	813.99	744.96	787.17	1,558.95	1,554.61	3,284.61
Total Expenses	2,162.40	1,999.44	1,871.94	4,161.84	3,693.96	7,581.05
Profit before Tax	1,158.36	946.37	1,027.70	2,104.73	1,976.94	3,313.50
Tax Expense						
Current Tax	207.28	171.21	146.97	378.49	356.17	606.96
Deferred Tax	(126.12)	(115.02)	(46.38)	(241.14)	(146.89)	(258.53)
Total Tax Expense	81.16	56.19	100.59	137.35	209.28	348.43
Net Profit for the period / year	1,077.20	890.18	927.11	1,967.38	1,767.66	2,965.07
Attributable to :						
- Owners of the Company	1,077.20	890.18	927.11	1,967.38	1,767.56	2,964.97
- Non controlling interest	-	-	-	-	0.10	0.10
Other Comprehensive Income	(12.08)	(1.42)	(0.77)	(13.50)	(4.60)	(12.18)
Items that will not be reclassified to profit or loss	(18.55)	(2.16)	(1.17)	(20.71)	(7.05)	(18.63)
Income tax relating to items that will not be reclassified to profit or loss	6.47	0.74	0.40	7.21	2.45	6.45
Total Comprehensive Income	1,065.12	888.76	926.34	1,953.88	1,763.06	2,952.89
Attributable to :						
- Owners of the Company	1,065.12	888.76	926.34	1,953.88	1,762.96	2,952.79
- Non controlling interest	-	-	-	-	0.10	0.10
Paid Up Equity Share Capital (Face Value of ₹ 1 each)	135.78	135.78	137.52	135.78	137.52	135.78
Other Equity						12,827.56
Earnings Per Share (of ₹ 1 each) (not annualised) :						
Basic	7.93	6.56	6.74	14.49	12.85	21.61
Diluted	7.93	6.55	6.73	14.48	12.84	21.59
See accompanying notes to the consolidated financial results						



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial result

1. Statement of Consolidated Assets and Liabilities

(₹ in Million)

Particulars	As at	As at
	September 30, 2020 (Unaudited)	March 31, 2020 (Audited)
I. ASSETS :		
(1) Non-current assets		
(a) Property, Plant and Equipment	734.22	812.51
(b) Right-of-use asset	44.46	60.28
(c) Goodwill	934.74	934.74
(d) Other Intangible assets	6,881.94	6,940.96
(e) Intangible assets under development	25.85	43.73
(f) Financial assets		
Investments	37.33	32.04
Other financial asset	93.88	83.12
(g) Income tax assets (net)	37.56	39.48
(h) Deferred tax assets (net)	1,952.13	1,709.11
(i) Other non-current assets	107.56	70.91
Total Non-current assets	10,849.67	10,726.88
(2) Current assets		
(a) Inventories	902.67	694.75
(b) Financial assets		
Investments	1,355.81	747.81
Trade receivables	1,945.89	1,568.84
Cash and cash equivalents	512.14	673.07
Other bank balances	0.20	0.19
Loans	8.34	9.35
Other financial assets	184.45	116.11
(c) Other current assets	1,087.76	986.05
Total Current assets	5,997.26	4,796.17
TOTAL- ASSETS	16,846.93	15,523.05
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	135.78	135.78
(b) Other Equity	14,043.72	12,827.56
Equity attributable to the owners of the Company	14,179.50	12,963.34
Non-controlling Interest	0.02	-
Total Equity	14,179.52	12,963.34
(2) Non-current liabilities		
(a) Financial Liabilities		
Lease Liabilities	51.13	61.44
Other financial liabilities	38.03	54.38
(b) Long-term provisions	312.95	259.77
(c) Other non-current liabilities	26.41	31.07
(d) Deferred tax liabilities (net)	500.74	506.15
Total Non-current liabilities	929.26	912.81
(3) Current liabilities		
(a) Financial Liabilities		
Trade payables		
A) Due to Micro and Small Enterprises	116.20	33.08
B) Due to other than Micro and Small Enterprises	878.09	967.43
Lease Liabilities	35.58	59.99
Other financial liabilities	59.64	16.20
Short term borrowings	1.50	-
(b) Short-term provisions	307.65	301.97
(c) Other current liabilities	213.06	198.25
(d) Income tax liabilities (net)	126.43	69.98
Total Current liabilities	1,738.15	1,646.90
Total Liabilities	2,667.41	2,559.71
TOTAL- EQUITY AND LIABILITIES	16,846.93	15,523.05



2. Statement of Consolidated Condensed Cash Flows for the Half Year ended September 30, 2020		
		(₹ in million)
Particulars	For the Half Year Ended September 30, 2020 (Unaudited)	For the Half Year Ended September 30, 2019 (Unaudited)
Net cash flow from operating activities		
Profit before tax	2,104.73	1,976.94
Operating profit before working capital changes	2,302.71	2,191.47
A) Net cash flow from operating activities	1,347.61	1,335.16
B) Net cash flow from/ (used in) investing activities	(714.51)	524.11
C) Net cash (used) in financing activities	(794.03)	(1,811.45)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(160.93)	47.82
Add : Cash and cash equivalents at the beginning of the period	673.07	75.00
Cash and cash equivalents at end of the period	512.14	122.82

3. The above statement of unaudited financial results ("the Statement") of the Group have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 03, 2020. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
4. The Group is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
5. The Group continues to observe the Covid-19 impact on its business. This covers the monitoring of its impact on its supply-chain and customers. Conclusions on significant accounting judgements and estimates have been drawn after exercising requisite due care. Such judgements and estimates include, inter-alia, recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available as of the date of preparing the Group's financial results for the quarter and half year ended September 30, 2020.
6. Other Income includes Net Gain/(Loss) on fair value of financial assets, net gain on sale of investments, interest income, deferred capital subsidy and sundry creditors written back.
7. The Parliament of India has approved the Code of Social security, 2020 ("the Code") which, inter alia, deals with employee benefits during employment and post employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified and the rules for quantifying the financial impact are also yet to be issued. In view of this, the impact of the change, if any, will be assessed and recognised post notification of the relevant provisions.
8. Figures for the previous periods / year have been regrouped wherever considered necessary.

For Eris Lifesciences Limited,



Amit Bakshi
Chairman and Managing Director
DIN : 01250925



Place: Ahmedabad
Date: November 03, 2020

